OBJECTIVE: The efficacy of atomoxetine as treatment of symptoms of attention-deficit/hyperactivity disorder (ADHD) in patients with autism spectrum disorder (ASD) has not been established. METHOD: In this study, 97 patients aged 6 to 17 years with ADHD and ASD were randomly assigned to double-blind treatment with 1.2 mg/kg/day atomoxetine or placebo for 8 weeks. The primary endpoint was the ADHD Rating Scale (ADHD-RS) score; secondary endpoints were the Clinical Global Impression of ADHD-Improvement (CGI-I) and the Conners Teacher Rating Scale-Revised: Short Form (CTRS-R:S) score. RESULTS:Baseline mean ADHD-RS scores for atomoxetine versus placebo were 40.7 and 38.6; after 8 weeks, mixed-effect model repeated-measure means were 31.6 (95% confidence interval 29.2-33.9) and 38.3 (36.0-40.6), respectively, with a difference in least square means of -6.7 (-10.0 to -3.4; p < .001). The CTRS-R:S Hyperactivity subscore also improved significantly for atomoxetine compared with placebo, but not the other CTRS-R:S subscores. However, there were not significantly more patients on atomoxetine (20.9%) who improved much, or very much according to the CGI-I, than on placebo (8.7%; p = 0.14). Adverse events (mostly nausea, decrease in appetite, fatigue, and early morning awakening) were reported in 81.3% of atomoxetine patients and 65.3% of placebo patients (p > .1). There were no serious adverse events. CONCLUSIONS:Atomoxetine moderately improved ADHD symptoms in patients with ASD and was generally well tolerated. Adverse events in this study were similar to those in other studies with ADHD patients without ASD. Clinical trial registration information-A Randomized Double-Blind Study of Atomoxetine Versus Placebo for ADHD Symptoms in Children with ASD; www.clinicaltrials.gov; NCT00380692.
RCT Entities:
OBJECTIVE: The efficacy of atomoxetine as treatment of symptoms of attention-deficit/hyperactivity disorder (ADHD) in patients with autism spectrum disorder (ASD) has not been established. METHOD: In this study, 97 patients aged 6 to 17 years with ADHD and ASD were randomly assigned to double-blind treatment with 1.2 mg/kg/day atomoxetine or placebo for 8 weeks. The primary endpoint was the ADHD Rating Scale (ADHD-RS) score; secondary endpoints were the Clinical Global Impression of ADHD-Improvement (CGI-I) and the Conners Teacher Rating Scale-Revised: Short Form (CTRS-R:S) score. RESULTS: Baseline mean ADHD-RS scores for atomoxetine versus placebo were 40.7 and 38.6; after 8 weeks, mixed-effect model repeated-measure means were 31.6 (95% confidence interval 29.2-33.9) and 38.3 (36.0-40.6), respectively, with a difference in least square means of -6.7 (-10.0 to -3.4; p < .001). The CTRS-R:S Hyperactivity subscore also improved significantly for atomoxetine compared with placebo, but not the other CTRS-R:S subscores. However, there were not significantly more patients on atomoxetine (20.9%) who improved much, or very much according to the CGI-I, than on placebo (8.7%; p = 0.14). Adverse events (mostly nausea, decrease in appetite, fatigue, and early morning awakening) were reported in 81.3% of atomoxetinepatients and 65.3% of placebo patients (p > .1). There were no serious adverse events. CONCLUSIONS:Atomoxetine moderately improved ADHD symptoms in patients with ASD and was generally well tolerated. Adverse events in this study were similar to those in other studies with ADHDpatients without ASD. Clinical trial registration information-A Randomized Double-Blind Study of Atomoxetine Versus Placebo for ADHD Symptoms in Children with ASD; www.clinicaltrials.gov; NCT00380692.
Authors: Benjamin L Handen; Michael G Aman; L Eugene Arnold; Susan L Hyman; Rameshwari V Tumuluru; Luc Lecavalier; Patricia Corbett-Dick; Xueliang Pan; Jill A Hollway; Kristin A Buchan-Page; Laura B Silverman; Nicole V Brown; Robert R Rice; Jessica Hellings; Daniel W Mruzek; Sarah McAuliffe-Bellin; Elizabeth A Hurt; Melissa M Ryan; Lynne Levato; Tristram Smith Journal: J Am Acad Child Adolesc Psychiatry Date: 2015-09-03 Impact factor: 8.829
Authors: Rameshwari V Tumuluru; Patricia Corbett-Dick; Michael G Aman; Tristram Smith; L Eugene Arnold; Xueliang Pan; Kristin A Buchan-Page; Nicole V Brown; Melissa M Ryan; Susan L Hyman; Jessica Hellings; Craig Williams; Jill A Hollway; Luc Lecavalier; Robert R Rice; Sarah McAuliffe-Bellin; Benjamin L Handen Journal: J Child Adolesc Psychopharmacol Date: 2017-05-16 Impact factor: 2.576
Authors: Evdokia Anagnostou; Lonnie Zwaigenbaum; Peter Szatmari; Eric Fombonne; Bridget A Fernandez; Marc Woodbury-Smith; Jessica Brian; Susan Bryson; Isabel M Smith; Irene Drmic; Janet A Buchanan; Wendy Roberts; Stephen W Scherer Journal: CMAJ Date: 2014-01-13 Impact factor: 8.262
Authors: Lawrence Scahill; Karen Bearss; Rena Sarhangian; Christopher J McDougle; L Eugene Arnold; Michael G Aman; James T McCracken; Elaine Tierney; Scott Gillespie; Valentina Postorino; Benedetto Vitiello Journal: J Child Adolesc Psychopharmacol Date: 2016-11-28 Impact factor: 2.576
Authors: Oliver D Howes; Maria Rogdaki; James L Findon; Robert H Wichers; Tony Charman; Bryan H King; Eva Loth; Gráinne M McAlonan; James T McCracken; Jeremy R Parr; Carol Povey; Paramala Santosh; Simon Wallace; Emily Simonoff; Declan G Murphy Journal: J Psychopharmacol Date: 2017-12-14 Impact factor: 4.153
Authors: Laura C Politte; Lawrence Scahill; Janet Figueroa; James T McCracken; Bryan King; Christopher J McDougle Journal: Neuropsychopharmacology Date: 2018-02-27 Impact factor: 7.853
Authors: Jill A Hollway; Marrisa Mendoza-Burcham; Rebecca Andridge; Michael G Aman; Benjamin Handen; L Eugene Arnold; Luc Lecavalier; Craig Williams; Laura Silverman; Tristram Smith Journal: J Child Adolesc Psychopharmacol Date: 2017-11-07 Impact factor: 2.576